ACHN: Achillion Pharmaceuticals, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Achillion Pharmaceuticals, Inc.

NASDAQ:ACHN

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$6.76
Loss Chance
58.4%
0.23JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
AbbVie
NYSE:ABBV
6.05
$215.70
118.45%
Alexion Pharmaceuticals
NASDAQ:ALXN
6.89
$182.50
52.20%
Amgen
NASDAQ:AMGN
6.24
$339.30
38.98%
Biogen
NASDAQ:BIIB
5.83
$193.76
12.58%
BioSpecifics Technologies Corp.
NASDAQ:BSTC
5.84
$88.53
68.60%
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (0)
Financial Strength (10)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Operating MarginInconsistent
Recent Business PerformanceEarning decline 19.79% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.23
100.00%
2.34
229.72%
2.34
229.72%
6.89
52.20%
6.17
95.57%
COMPANY DESCRIPTION
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
www.achillion.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.